Sputtr.com | Alternative Search Engine


about biotechnology

Major recent investments in bio processing and related pharmaceutical projects - £450M & 1700 jobs from 2003 to 2006 including - Avecia Biologics (Teesside), sanofi-aventis (Tyne & Wear), SSLInternational (Durham), Lundbeck Pharmaceuticals (Teesside), The Specials Laboratory (Northumberland ...

Development of materials within PolyApply

As a step towards simpler processing, Avecia has developed a range of polym eric semiconductors with mobilities reaching 0.01 cm2V-1s-1. Being amorp hous, they are insensitive to the dep osition conditions and offer greater flexibility for optimizing the device structure.

PRESS RELEASE - Fujifilm Diosynth Biotechnologies

Billingham, UK (MSD Biologics (UK) Ltd, formerly Avecia Biologics) and Research Triangle Park, NC, USA (Diosynth RTP LLC). Yuzo Toda, General Manager of Pharmaceutical Products Division, FUJIFILM

Handley and Geoffrey D. Robson Nixon, Ian M. Eastwood ...

Office in collaboration with Avecia Ltd., United Kingdom. REFERENCES 1. Baldwin, B. C., and T. E. Wiggins. 1984. Action of fungicidal triazoles of the

Pharma visions

The headquarters of the group are located in Pompey, France, and Roger-Marc Nicoud is the new president and CEO of the combined company. Avecia's Hexagon Tower, Manchester, UK: housing dedicated facilities for Reaxa Ltd.

Extending capacity and reach in bioprocessing

Founding company members of BRIC: Antisoma, Avacta plc, Avecia Biologics, Centre of Excellence for Life Sciences, Cobra Biomanufacturing, Eden Biopharm, Glycoform, GlaxoSmithKline, HPA, Ipsen Limited, Lonza Biologics plc, Med Cell Bioscience Ltd, MedImmune, Millipore, NIBSC, Novozymes Delta Ltd, Pall ...


Avecia will carry out projects for Merck & Co., and for Avecia‟s customers. "Very clearly we will not walk away from any of our existing customer contracts," Taylor says.

Ink Jet Printing - Developers Conference 2002

a unique breadth of technological capabilities Avecia is the ideal ink partner for your application. Contact: Dr Neil Cullum Business Development Manager

GBIHC048MR-Downstream Processing in Biopharmaceuticals Sample ...

Figure 46: Downstream Processing, Key CMO Players, SWOT Analysis, Avecia, 2009.....84 Figure 47: Downstream Processing, Key CMO Players, Business Overview, Diosynth


Globalisation at a glance • Exports of APIs and formulations made to various global markets • Pioneer in custom manufacturing - positioned as "partner of choice"for global innovator companies • CRAMS business made stronger with the acquisition of Avecia in UK • Manufacturing facilities in UK ...